公开(公告)号：US20230399616A1

公开(公告)日：2023-12-14

申请号：US18251030

申请日：2021-10-29

申请人： Westlake Therapeutics (Hangzhou) Co. Limited

发明人： Xiaofei Gao ,  Yanjie Huang ,  Xiaoqian Nie

IPC分类号： C12N5/078 ,  C12N9/52

CPC分类号： C12N5/0641 ,  C12N9/52 ,  C12Y304/2207

摘要： Provided is a method for covalently modifying at least one membrane protein of a red blood cell (RBC), comprising contacting the RBC with a sortase substrate that comprises a sortase recognition motif and an agent, in the presence of a sortase under conditions suitable for the sortase to conjugate the sortase substrate to the at least one membrane protein of the RBC by a sortase-mediated reaction, wherein the sortase recognition motif comprising an optionally substituted hydroxyl carboxylic acid d located at position 5 from the direction of N-terminal to C-terminal. Also provided is a red blood cell (RBC) having an agent linked thereto obtained by the method, as well as the use of the RBC for delivering agents such as drugs and probes.

公开(公告)号：US20230145118A1

公开(公告)日：2023-05-11

申请号：US17906435

申请日：2021-03-19

申请人： Westlake Therapeutics (Hangzhou) Co. Limited

发明人： Xiaofei Gao ,  Yanjie Huang ,  Jia Dong ,  Xiaoqian Nie

IPC分类号： A61K47/69 ,  C12N5/00 ,  C12N5/078 ,  C12N9/52 ,  A61K38/48 ,  C12N9/96 ,  A61K35/18 ,  A61P31/14

CPC分类号： A61K47/6901 ,  C12N5/0006 ,  C12N5/0641 ,  C12N9/52 ,  C12Y304/2207 ,  A61K38/4813 ,  C12Y304/17023 ,  C12N9/96 ,  A61K35/18 ,  A61P31/14 ,  C07K2319/30

摘要： A red blood cell (RBC) having an agent linked thereto, wherein the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by a sortase-mediated reaction, preferably by a sortase-mediated glycine conjugation and/or a sortase-mediated lysine side chain ε-amino group conjugation, which may occurring at least on glycine (n) and/or lysine ε-amino group at internal sites of the extracellular domain of at least one endogenous, non-engineered membrane protein, preferably n being 1 or 2, as well as the use of the RBC for delivering drugs and probes.

公开(公告)号：US20240228983A1

公开(公告)日：2024-07-11

申请号：US18264098

申请日：2022-01-30

申请人： Westlake Therapeutics (Hangzhou) Co. Limited

发明人： Xiaofei Gao ,  Xiaoqian Nie ,  Jun Ren ,  Yanjie Huang ,  Xuan Liu ,  Lu Liu

IPC分类号： C12N9/06 ,  A61K35/18 ,  A61P3/00 ,  C12N5/078 ,  C12P21/06

CPC分类号： C12N9/0048 ,  A61K35/18 ,  A61P3/00 ,  C12N5/0641 ,  C12P21/06

摘要： Provided are a red blood cell (RBC) having an agent linked thereto, wherein the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by a sortase-mediated glycine conjugation or lysine side chain ε-amino group conjugation, and wherein the agent comprises a uric acid degrading polypeptide, a uric acid transporter or the combination; a method for preparing the RBC; and the use of the RBC for preventing or treating a disorder, condition or disease associated with an elevated uric acid level including hyperuricemia or gout.

公开(公告)号：US20240043802A1

公开(公告)日：2024-02-08

申请号：US17595183

申请日：2019-05-13

申请人： WESTLAKE THERAPEUTICS (HANGZHOU) CO. LIMITED

发明人： Xiaofei GAO ,  Yanjie HUANG ,  Dandan LI

IPC分类号： C12N5/078 ,  C12N15/86 ,  C07K16/28

CPC分类号： C12N5/0641 ,  C12N15/86 ,  C07K16/2818 ,  C12N2510/00 ,  C12N2506/11 ,  C12N2740/15043 ,  C12N2501/125 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2500/32 ,  C12N2501/33 ,  C12N2501/998 ,  C12N2501/14 ,  C07K2317/622

摘要： Provided are a method for preparing genetically engineered erythrocytes carrying an anti-PD-1 single chain antibody, and genetically engineered erythrocytes carrying the anti-PD-1 single chain antibody. The preparation method comprises the following steps: constructing a desired fragment sequence in a lentiviral expression vector, lentivirally packaging the vector of the desired sequence to obtain a high-titer lentiviral concentrate; isolating Lin−CD34− cells from peripheral blood mononuclear cells and enriching the Lin−CD34− cells; inducing the Lin−CD34− cells to differentiate into erythroid and performing proliferation thereon; using the lentiviral concentrate to infect the Lin−CD34− cells; and obtaining mature anti-PD-1 scFv erythrocytes via erythrocyte denucleation. The present genetically engineered erythrocytes carrying the anti-PD-1 single chain antibody can perform the targeted delivery of an anti-PD-1 single-chain antibody to tumor tissues.

公开(公告)号：US20220112463A1

公开(公告)日：2022-04-14

申请号：US17430020

申请日：2020-02-26

申请人： WESTLAKE THERAPEUTICS (HANGZHOU) CO. LIMITED

发明人： Xiaofei GAO ,  Yanjie HUANG ,  Qing ZHANG

IPC分类号： C12N5/078

摘要： The present disclosure provides a method for producing red blood cells by using peripheral blood as well as the produced red blood cells.